Collaboration partner Sanofi S.A. notified Nurix Therapeutics, Inc. on November 3, 2026, that it is discontinuing the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and terminating the program entirely. Consequently, Nurix does not expect to receive any future development, regulatory, or commercial milestone payments or royalties associated with this specific program under their collaboration agreement. The company remains eligible for potential milestones and royalties regarding other licensed programs within the Sanofi Collaboration that may be advanced by the partner. Nurix Therapeutics operates in the biotechnology industry, focusing on targeted protein degradation therapies.
